Literature DB >> 25940985

Head and neck cancer: second-line afatinib shows promise.

David Killock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25940985     DOI： 10.1038/nrclinonc.2015.86

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.

Authors:  Jean-Pascal H Machiels; Robert I Haddad; Jérôme Fayette; Lisa F Licitra; Makoto Tahara; Jan B Vermorken; Paul M Clement; Thomas Gauler; Didier Cupissol; Juan José Grau; Joël Guigay; Francesco Caponigro; Gilberto de Castro; Luciano de Souza Viana; Ulrich Keilholz; Joseph M Del Campo; Xiuyu Julie Cong; Eva Ehrnrooth; Ezra E W Cohen
Journal:  Lancet Oncol       Date:  2015-04-16       Impact factor: 41.316
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.